Outcry Continues to Grow for Johnson & Johnson to Resolve Talc-Cancer Claims After Latest Jury Verdict

- Another jury has found that Johnson & Johnson's (NYSE:JNJ) talcum powder products cause cancer, prompting attorneys representing thousands of cancer victims to demand that the company take responsibility for damages brought by its defective consumer products and its failure to warn generations of women about talc-cancer links.

The $26.5 million verdict by a California jury on August 26 continues to send a message – amplified in numerous earlier trials – that decades of hiding the truth about the carcinogenic properties of talcum powder must end, says an attorney who's leading the fight against J&J.

"The evidence from J&J's own records clearly shows a 50-year-old pattern of corporate cover-ups and manipulation of research on the dangers of talc use," said Andy Birchfield , head of the Mass Torts Section at the Beasley Allen Law Firm . "This verdict is just the latest step in exposing the shameful lengths this company went through to keep selling its iconic product while putting lives in danger."

Jurors in Alameda County awarded $26.5 million in compensatory damages against J&J for causing the mesothelioma cancer of 35-year-old Christina Prudencio , a former teacher. According to trial testimony of her mother and sister, Ms. Prudencio was directly and indirectly exposed to Johnson's Baby Powder for more than two decades.

Several jury trials and news reports in recent years have documented that J&J's talc-based products – including Johnson's Baby Powder and Shower to Shower – were sometimes tainted with carcinogenic asbestos and that J&J historically kept that information from regulators and the public. Last year, the U.S. Food and Drug Administration released a report that found roughly 20 percent of talc-based powders and makeup samples tested by the agency contained asbestos.

In May 2020 , Johnson & Johnson announced the company would no longer make or market talc-based powders for the North American market. In June, the U.S. Supreme Court declined to hear evidence from a $2.1 billion judgment against the company entered by the Missouri Court of Appeals and upheld by the Missouri Supreme Court. That appellate court found that J&J had engaged in "reprehensible conduct" for decades by repeatedly denying the known association between talc use and ovarian cancer.

In response to ongoing litigation and mounting jury verdicts, the company has threatened to bundle those liabilities into a separate entity, which would then seek bankruptcy protection. Such a scheme would eliminate the rights of thousands of ovarian cancer victims to have their claims resolved before a judge and jury.

"Rather than attempt a cynical, greedy ploy to seek insolvency for a $500 billion company, J&J should simply come clean and seek a resolution that acknowledges the company's negligence and establishes a means for fairly compensating victims both now and in the future," said Birchfield.

Media Contact:

Mike Androvett
214-507-5456
mike@androvett.com

Cision View original content: https://www.prnewswire.com/news-releases/outcry-continues-to-grow-for-johnson--johnson-to-resolve-talc-cancer-claims-after-latest-jury-verdict-301366432.html

SOURCE Beasley Allen Law Firm

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.

This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and prevention of diseases and physical conditions, and it continues to develop rapidly.

Examples of medical devices include neurostimulation devices, surgical implants, ultrasound imaging devices and robotic medical technology, along with insulin pumps and insulin pens for diabetes. Just as pharmaceutical companies seek to serve unmet needs, medical device companies do the same via innovative technologies.

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Latest Press Releases

Related News

×